Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Bullboard Posts
Post by PivotPointNewsWireon Dec 19, 2012 9:48pm
275 Views
Post# 20753566

Visual Impairment Increasing In U.S. From Macular

Visual Impairment Increasing In U.S. From Macular

https://www.huffingtonpost.com/2012/12/11/visual-impairment-macular-degeneration-diabetic-retinopathy-_n_2278192.html#slide=1154640

Visual Impairment Increasing In U.S. From Macular Degeneration, Diabetic Retinopathy: Study

Visual Impairment

The number of people who are in the process of losing their sight from conditions such as macular degeneration, diabetic retinopathy, glaucoma and cataracts is increasing in the United States, according to a new study in the Journal of the American Medical Association.

"If the current finding becomes a persisting trend, it could result in increasing rates of disability in the U.S. population, including greater numbers of patients with end-organ diabetic damage who would require ophthalmic care," the researchers, from Johns Hopkins University School of Medicine, wrote in the study.

The study included 9,471 people ages 20 and older who were part of the National Health and Nutrition Examination Survey between 1999 and 2002, as well as 10,480 people ages 20 and older who were part of the survey between 2005 and 2008.

Researchers found a 21 percent increase in nonrefractive visual impairments -- meaning visual impairments not caused by the common problems of nearsightedness, farsightedness and astigmatism -- between the 1999-2002 period and the 2005-2008 period. Specifically, 1.4 percent of people had these kinds of visual impairments between 1999 and 2002, compared with 1.7 percent of people between 2005 and 2008.

Non-Hispanic white people between ages 20 and 39 had a 40 percent increase in nonrefractive visual impairments, with the prevalence going up from 0.5 percent in 1999-2002 to 0.7 percent in 2005-2008.

Researchers reported that factors such as poverty, diabetes and lower education level are all linked with these kinds of visual impairments, but that only diabetes has actually increased between the two time periods -- suggesting that it could play a role in the increased rates.

"The prevalence of diagnosed diabetes has increased among adults in recent years, rising from 4.9 percent in 1990 to 6.5 percent in 1998, 7.9 percent in 2001, 10.7 percent in 2007, and 11.3 percent in 2010," the researchers wrote in the study.

PPNW

https://www.pivotpointnewswire.com/

Bullboard Posts